Clinical Efficacy of Atorvastatin Combined with Ezetimibe in Preventing Restenosis after Coronary Artery Bypass Grafting
Tianjin Medical University Heping, Wuqing, Tianjin 300070, 1Department of Cardiovascular Surgery, Tangshan Workers’ Hospital, Tangshan, Hebei Province 063000, 2Department of Stomatology, North China University of Science and Technology, Tangshan, Hebei 063210, 3Department of Cardiovascular Surgery, Tianjin Chest Hospital, Jinnan, Tianjin 300300, China
Qing Liang Chen, Department of Cardiovascular Surgery, Tianjin Chest Hospital, Jinnan, Tianjin 300300, China, E-mail: email@example.com
To investigate the clinical efficacy of atorvastatin combined with ezetimibe in preventing restenosis after coronary artery bypass grafting. Total 100 patients in Tangshan Workers’ Hospital were randomly divided into observation group and control group. The control group received 100 mg aspirin, 75 mg clopidogrel and atorvastatin 20 mg once a day. The observation group was given 10 mg ezetimibe once a day in addition to the above drugs. The venous diameter, blood lipid level changes, inflammatory response, quality of life, adverse reactions and treatment effects were assessed. After treatment for 6 mo, hypersensitive C-reactive protein and interleukin-6 levels were lower in observation group than control group. Total cholesterol, triglyceride and low-density lipoprotein cholesterol levels were lower and high-density lipoprotein cholesterol level was higher in observation group than control group. The observation group exhibited higher rates of vein garft stenosis improvement, lower rates of disease progression, lower incidence of major adverse cardiovascular events and higher 36-Item Short-Form Health survey scores than control group. The efficacy of ezetimibe combined with atorvastatin in treating restenosis after coronary artery bypass grafting is good, which also controls blood lipids with low incidence of adverse reactions.